人乳头瘤病毒感染生物学与HPV相关头颈癌的免疫治疗
Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers.
作者信息
Best Simon R, Niparko Kevin J, Pai Sara I
机构信息
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, 601 North Caroline Street, JHOC 6th floor, Baltimore, MD 21287, USA.
出版信息
Otolaryngol Clin North Am. 2012 Aug;45(4):807-22. doi: 10.1016/j.otc.2012.04.005.
Abstract
This article outlines the biology of human papillomavirus (HPV) infection of human mucosa and the cellular pathways that are altered through viral infection. The article provides a conceptual framework with which to understand the 2 major immunologic strategies to address HPV-related diseases: (1) prevention of primary HPV infection through the use of prophylactic vaccines and (2) treatment of established infection and diseases through therapeutic vaccines. Nonimmunologic therapy that targets cellular dysregulation induced by HPV infection is also discussed. The challenges in actualizing these conceptually attractive therapies on both a societal and biological level are examined.
摘要
本文概述了人乳头瘤病毒（HPV）对人体黏膜的感染生物学以及病毒感染后发生改变的细胞途径。本文提供了一个概念框架，用以理解应对HPV相关疾病的两种主要免疫策略：（1）通过使用预防性疫苗预防HPV原发性感染；（2）通过治疗性疫苗治疗已确诊的感染和疾病。本文还讨论了针对HPV感染引起的细胞失调的非免疫疗法。研究了在社会和生物学层面实现这些理论上颇具吸引力的疗法所面临的挑战。
相似文献
1
Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers.
Otolaryngol Clin North Am. 2012 Aug;45(4):807-22. doi: 10.1016/j.otc.2012.04.005.
2
Manifestations of Human Papillomavirus in the Head and Neck.
Med Clin North Am. 2021 Sep;105(5):849-858. doi: 10.1016/j.mcna.2021.05.007.
3
Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases.
Cancer. 2017 Jun 15;123(12):2219-2229. doi: 10.1002/cncr.30588. Epub 2017 Mar 27.
4
Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
Immunol Rev. 2011 Jan;239(1):85-98. doi: 10.1111/j.1600-065X.2010.00966.x.
5
The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
Virus Res. 2017 Mar 2;231:148-165. doi: 10.1016/j.virusres.2016.12.002. Epub 2016 Dec 6.
6
Perspectives for the development of human papillomavirus vaccines and immunotherapy.
Expert Rev Vaccines. 2010 Jan;9(1):35-44. doi: 10.1586/erv.09.145.
7
Human Papillomavirus and Oropharyngeal Cancer.
Dent Clin North Am. 2018 Jan;62(1):111-120. doi: 10.1016/j.cden.2017.08.008. Epub 2017 Oct 7.
8
Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer.
Semin Radiat Oncol. 2012 Jul;22(3):194-7. doi: 10.1016/j.semradonc.2012.03.003.
9
Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.
Hum Gene Ther. 2018 Sep;29(9):971-996. doi: 10.1089/hum.2017.197. Epub 2018 Mar 16.
10
The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.
Cancer. 2016 Aug 1;122(15):2313-23. doi: 10.1002/cncr.29992. Epub 2016 May 6.
引用本文的文献
1
Medicinal Mushrooms, Probiotics and Combination of Natural Compounds in the Management of HPV: A Comparative Look at Viral Clearance and Lesion Resolution.
Viruses. 2025 Jul 2;17(7):942. doi: 10.3390/v17070942.
2
Genetic variability in HPV 33 and 35 E6 and E7 genes from South African and Mozambican women with different cervical cytology status.
Virol J. 2025 Jul 10;22(1):234. doi: 10.1186/s12985-025-02851-2.
3
Empirical sample-specific approaches to define HPV16 and HPV18 seropositivity in unvaccinated, young, sexually active women.
Microbiol Spectr. 2024 Jun 4;12(6):e0022924. doi: 10.1128/spectrum.00229-24. Epub 2024 Apr 30.
4
Network-based drug repurposing for HPV-associated cervical cancer.
Comput Struct Biotechnol J. 2023 Oct 19;21:5186-5200. doi: 10.1016/j.csbj.2023.10.038. eCollection 2023.
5
HPV16 Impacts NHERF2 Expression in Oropharyngeal Cancers.
Pathogens. 2023 Aug 3;12(8):1013. doi: 10.3390/pathogens12081013.
6
Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems.
Pathogens. 2022 Nov 30;11(12):1444. doi: 10.3390/pathogens11121444.
7
Systematic Analysis of IL-1 Cytokine Signaling Suppression by HPV16 Oncoproteins.
J Virol. 2022 Nov 23;96(22):e0132622. doi: 10.1128/jvi.01326-22. Epub 2022 Nov 7.
8
Antiproliferative and Pro-Apoptotic Effects of a Phenolic-Rich Extract from Fruits on Human Papillomavirus (HPV) 16-Positive Head Cancer Cell Lines.
Molecules. 2022 Jun 2;27(11):3568. doi: 10.3390/molecules27113568.
9
Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer.
Oncoimmunology. 2021 Jun 12;10(1):1936391. doi: 10.1080/2162402X.2021.1936391.
10
Prognostic implication of human papillomavirus types in cervical cancer patients: a systematic review and meta-analysis.
Infect Agent Cancer. 2020 Nov 7;15(1):66. doi: 10.1186/s13027-020-00332-5.
本文引用的文献
1
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States.
J Clin Oncol. 2023 Jun 10;41(17):3081-3088. doi: 10.1200/JCO.22.02625.
2
Prevalence of oral HPV infection in the United States, 2009-2010.
JAMA. 2012 Feb 15;307(7):693-703. doi: 10.1001/jama.2012.101. Epub 2012 Jan 26.
3
Human papillomavirus and rising oropharyngeal cancer incidence in the United States.
J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3.
4
National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010.
MMWR Morb Mortal Wkly Rep. 2011 Aug 26;60(33):1117-23.
5
Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer.
Br J Cancer. 2011 Jun 7;104(12):1896-905. doi: 10.1038/bjc.2011.171.
6
Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Epidemiology. 2011 Jul;22(4):505-15. doi: 10.1097/EDE.0b013e31821d107b.
7
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study.
Lancet. 2011 Mar 12;377(9769):932-40. doi: 10.1016/S0140-6736(10)62342-2. Epub 2011 Feb 28.
8
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.
N Engl J Med. 2011 Feb 3;364(5):401-11. doi: 10.1056/NEJMoa0909537.
9
Expression of human papillomavirus type 16 E7 is sufficient to significantly increase expression of angiogenic factors but is not sufficient to induce endothelial cell migration.
Virology. 2011 Feb 20;410(2):283-90. doi: 10.1016/j.virol.2010.11.010. Epub 2010 Dec 14.
10
Differential expression of epidermal growth factor receptor in juvenile and adult-onset recurrent respiratory papillomatosis.
Histopathology. 2010 Nov;57(5):768-70. doi: 10.1111/j.1365-2559.2010.03691.x.
Zotero 插件